Roivant Sciences Ltd. (ROIV) Stock

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is led by CEO Matthew Gline, employs 721 people, headquartered in London, GB, publicly traded since 2020.

Roivant Sciences Ltd. (ROIV) stock trades at $36.49 with a market capitalization of $26.36B. The stock is valued at a negative price-to-earnings (P/E) ratio of -94.21, reflecting a net loss over the last twelve months, price-to-book of 6.10, price-to-sales of 3433.63. Over the past 52 weeks the stock has ranged between $14.86 and $42.50, and currently trades 14.1% below its 52-week high.

On profitability, Roivant Sciences Ltd. generates a return on equity (ROE) of -6.12% (negative, reflecting a net loss), return on capital employed of -27.20%, an operating margin of -3458.62%, a net profit margin of -60.80%.

In its most recent fiscal year, Roivant Sciences Ltd. reported annual revenue of $8.0M, a net loss of $300.0M. Revenue declined at an average annual rate of 19.7% over the last 5 fiscal years.

The balance sheet shows a debt-to-equity ratio of 0.03 (debt below half of shareholders' equity), a current ratio of 33.56, total assets of $5.7B, $1.4B in cash and equivalents.

ROIV has an average daily trading volume of 6,784,921 shares, a beta of 1.12.

Roivant Sciences Ltd. by the numbers, 2019–2025

Between 2019 and 2025 Roivant Sciences Ltd. reported revenue of $68.0M rising to $8.0M, a change of -88.2% across 7 years. Compounded, revenue has grown -19.7% a year over five years, -37.0% over three, -72.4% over the last twelve months. Net profit fell to $-300.0M.

Operating margin went from -786.6% in 2019 to -15560.6% in 2025, a fall of 14774.0 percentage points. The most recent net margin is -60.80%. On a trailing twelve-month basis to Jun '26, revenue is $8.0M and net profit $-267.0M.

Borrowings fell from $181.0M to $107.0M, cash from operations was $-750.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -15.1% over five years, and was -6.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Roivant Sciences Ltd. (ROIV) — frequently asked questions